Tumor suppression by modulating stem cell fitness. James DeGregori University of Colorado Denver School of Medicine
|
|
- Nickolas Bell
- 5 years ago
- Views:
Transcription
1 Tumor suppression by modulating stem cell fitness James DeGregori University of Colorado Denver School of Medicine
2 Natural Selection can explain cancer incidence at the species level Intrinsic TS Integral TS Age Ø The evolution of long-lived multicellular animals required the selection for potent tumor suppressive mechanisms. Ø There is minimal selection against cancer beyond the age where most animals would already be dead by other causes. Ø Better tumor suppression would require additional energy in early life, which would come with a cost.
3 Conventional View é Number of oncogenic mutations Cancer Adaptive Oncogenesis Model Healthy, Young Low Environmental Insult; Aging ê Cell Fitness, Altered Microenvironment Fitness é Selection for adaptive mutations Cancer High
4 High stem cell pool fitness is tumor suppressive Malignant genotypes D Malignant genotypes WT genotype Fitness WT genotype Young, healthy stem cell pool D Old or damaged stem cell pool D DeGregori, J. (2011). Evolved tumor suppression: why are we so good at not getting cancer? Cancer Research, 71:
5 Model for how vertebrates with large differences in somatic cell numbers and lifespans similarly avoid cancer through reproductive years. Increased risk of somatic evolution in larger animals Decreased risk of somatic evolution in larger animals Is the effective population size for SCs bigger in bigger animals? SC number/tissue: target size for oncogenic hits Lifespan (time available to accumulate mutations) Buffering capacity of tissue to maintain fitness Chance of mutation fixation by drift Ability of a fit stem cell pool to impede somatic cell evolution
6 Why does cancer increase with age? Accumula'on of oncogenic muta'ons. Changes in cellular microenvironment. Chronic inflamma'on. Decreased immune surveillance. Does reduc*on of cellular fitness lead to selec*on for specific adap*ve oncogenic muta*ons?
7 Signaling in B- progenitors Declines with Age Henry et. al; PNAS; December 14, 2010 vol. 107 no
8 Bcr- Abl Becomes Adap*ve in Aged Backgrounds by Allevia*ng Aging- Associated Signaling Defects Henry et. al; PNAS; December 14, 2010 vol. 107 no
9 Ø Signaling defects in old B-progenitors contribute to reduced fitness (as determined using competitive transplantation assays. Ø Bcr-Abl restores signaling, promoting selection for Bcr-Abl expression. Ø Selection for Bcr-Abl within old B-progenitor pools leads to increased leukemogenesis. Henry et. al; PNAS; December 14, 2010 vol. 107 no
10 What else underlies fitness defects in old B-progenitors?
11 Anabolic and catabolic pathways decrease in old B-progenitors
12 Aging is not a program but programs can mediate aging and aging can be deprogrammed.
13 Old B Cell Progenitors Exhibit Metabolic Defects 1.0 TCA Cycle Intermediates Energy Lactate TCA p=0.01 p=0.018 p=0.032 n.s. p= p= Rela*ve Amount Citrate Y Citrate O Glutamine Y Glutamine O Glutamate Y Glutamate O 0.0 Adenosines Y Adenosines O Creatine Y Creatine O 0.0 Lactate Y Lactate O
14 ATP Levels are Decreased in Old B cell Progenitors Relative to Young Ones 80 p< Relative ATP amount Young Y B220 B cell Progenitors Old O B220 Young Myeloid Cells Old
15 Model for Bcr-Abl Adaptation in an Aged Background Young B cell Progenitors Old B cell Progenitors Old B cell Progenitors + Bcr- Abl anabolism anabolism
16 A. Predominant Model Aging Accumula'on of deleterious muta'ons Accumula'on of oncogenic muta'ons Decline in progenitor cell fitness and 'ssue func'on Cancer B. Adap've Oncogenesis Model Aging Accumula'on of deleterious muta'ons, epigene'c changes & microenvironmental perturba'ons Accumula'on of oncogenic muta'ons Decline in progenitor cell fitness and 'ssue func'on Increased selec'on for adap$ve oncogenic muta'ons Cancer
17 2.5-5Gy Previous Irradiation (IR P ) 2 months IR P IR P Number of Lin neg Sca1 + Cells Day7 # Lin neg Sca1 +
18 Prior irradiation and HSC fitness Previously irradiated HSC exhibit maintenance defects that are specific, reproducible, somatically heritable, and reversible. Evolved to deal with the occasionally damaged cell? Programmed Mediocrity? Occasional Damaged Cell Will be weeded out Total Body Irradiation
19 Hmmm. Could programmed mediocrity be a mechanism to maintain tissue fitness in youth, but which contributes to tissue decline in old age?
20 THE LAB Francesca Alvarez-Calderon Mark Gregory *Courtney Fleenor *Curtis Henry Vadym Zaberezhnyy *Matias Casas Selves Rodrigo Maegawa *Biniam Adane THE $$$ NCI/NIA Flow Cytometry Karen Helm Christine Childs Former: *Andriy Marusyk Other Natalie Serkova Andrea Mertz Art work: Michael and Gayle DeGregori
21 So why do kids get cancer? 1) Given expansion of progenitor populations, a mutation can more easily become fixed even if not advantageous. 2) More recent evolution has substantially altered the human brain and immune systems, and a low risk of childhood leukemias affecting these tissues has been a tradeoff (although advantages of a more developed brain and better immune system outweighed the low leukemia risk). 3) There are dietary and genetic factors which correlate with reduced folate and/or reduced dntp synthesis, which may reduce progenitor fitness, and thus may contribute to childhood cancers. 4) Our immune systems did not evolve to deal with modern conditions, but to conditions with more antigen and pathogen exposures early in life. Thus, our hematopoietic systems are not truly adapted to modern life. 5) Translocations common to childhood leukemias are more likely to occur in fetal or childhood development.
Impaired DNA replication within progenitor cell pools promotes leukemogenesis
Impaired DNA replication within progenitor cell pools promotes leukemogenesis Ganna Bilousova, University of Colorado Andriy Marusyk, University of Colorado Christopher Porter, Emory University Robert
More informationAging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors
Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors Curtis J. Henry, 1,2 Matias Casás-Selves, 1 Jihye Kim, 3 Vadym Zaberezhnyy, 1 Leila Aghili, 1 Ashley
More informationThe evolution of lifespan and age-dependent cancer risk
The evolution of lifespan and age-dependent cancer risk Andrii I. Rozhok 1 and James DeGregori 1,2,3,4 1 Department of Biochemistry and Molecular Genetics, 2 Integrated Department of Immunology, 3 Department
More informationStochastic modeling indicates that aging and somatic evolution in the hematopoietic system are driven by non cell autonomous processes
www.impactaging.com AGING, December 2014, Vol 6, N 12 Research Paper Stochastic modeling indicates that aging and somatic evolution in the hematopoietic system are driven by non cell autonomous processes
More informationToward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations
Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations Andrii I. Rozhok a and James DeGregori a,b,c,d,1 a Department of Biochemistry and Molecular
More informationIonizing radiation and hematopoietic malignancies Altering the adaptive landscape
review Cell Cycle 9:15, 3005-3011; August 1, 2010; 2010 Landes Bioscience REVIEW Ionizing radiation and hematopoietic malignancies Altering the adaptive landscape Courtney J. Fleenor, 1,3 Andriy Marusyk
More informationHaematopoietic stem cells
Haematopoietic stem cells Neil P. Rodrigues, DPhil NIH Centre for Biomedical Research Excellence in Stem Cell Biology Boston University School of Medicine neil.rodrigues@imm.ox.ac.uk Haematopoiesis: An
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationDISCLOSURE. I have the following financial relationships:
DISCLOSURE I have the following financial relationships: Consultant for: Fate Therapeutics, GlaxoSmithKline, Bone Therapeutics, G1 Therapeutics Contracted Research for: GlaxoSmithKline Royalties from:
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationThe Hierarchical Organization of Normal and Malignant Hematopoiesis
The Hierarchical Organization of Normal and Malignant Hematopoiesis NORMAL Hematopoie2c Stem Cell (HSC) Leukemia Stem Cells (LSC) MPP MLP CMP Leukemic Progenitors MEP GMP B/NK ETP Leukemic Blasts Erythrocytes
More informationHematopoiesis. - Process of generation of mature blood cells. - Daily turnover of blood cells (70 kg human)
Hematopoiesis - Process of generation of mature blood cells - Daily turnover of blood cells (70 kg human) 1,000,000,000,000 total cells 200,000,000,000 red blood cells 70,000,000,000 neutrophils Hematopoiesis
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature11095 Supplementary Table 1. Summary of the binding between Angptls and various Igdomain containing receptors as determined by flow cytometry analysis. The results were summarized from
More informationHeterogeneity of Abnormal RUNX1 Leading to Clinicopathological Variations in Childhood B-Lymphoblastic Leukemia
Heterogeneity of Abnormal RUNX1 Leading to Clinicopathological Variations in Childhood B-Lymphoblastic Leukemia Xiayuan Liang, MD Department of Pathology University of Colorado School of Medicine Children
More informationNicholas Chiorazzi The Feinstein Ins3tute for Medical Research Northwell Health Manhasset, NY
A Somewhat Different View of the Gene3c Portrait of Chronic Lymphocy3c Leukemia Nicholas Chiorazzi The Feinstein Ins3tute for Medical Research Northwell Health Manhasset, NY Acknowledgments Davide Bagnara
More information11.1 Genetic Variation Within Population. KEY CONCEPT A population shares a common gene pool.
KEY CONCEPT A population shares a common gene pool. Genetic variation in a population increases the chance that some individuals will survive. Genetic variation leads to phenotypic variation. Phenotypic
More informationAML Genomics 11/27/17. Normal neutrophil maturation. Acute Myeloid Leukemia (AML) = block in differentiation. Myelomonocy9c FAB M5
AML Genomics 1 Normal neutrophil maturation Acute Myeloid Leukemia (AML) = block in differentiation AML with minimal differen9a9on FAB M1 Promyelocy9c leukemia FAB M3 Myelomonocy9c FAB M5 2 1 Principle
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationMeeting Report. From December 8 to 11, 2012 at Atlanta, GA, U.S.A
Meeting Report Affiliation Department of Transfusion Medicine and Cell Therapy Name Hisayuki Yao Name of the meeting Period and venue Type of your presentation Title of your presentation The 54 th Annual
More informationMETABOLIC VULNERABILITIES OF CANCER. Eyal Gottlieb
METABOLIC VULNERABILITIES OF CANCER Eyal Gottlieb METABOLIC VULNERABILITIES OF CANCER Eyal Gottlieb Cancer and metabolism: the anabolic angle glucose glucose-6-phosphate Ribose-5-phosphate ADP + Pi Serine
More informationMolecular Characterization of Leukemia Stem Cell Development. Scott A. Armstrong MD, Ph.D.
Molecular Characterization of Leukemia Stem Cell Development Scott A. Armstrong MD, Ph.D. Normal and Leukemic Hierarchies NORMAL HSC (SRC) Myeloid progenitor LTC-IC CFU AML LSC (SL-IC) Leukemic LTC-IC
More informationTITLE: Effects of Hematopoietic Stem Cell Age on CML Disease Progression
AD Award Number: W81XWH-04-1-0795 TITLE: Effects of Hematopoietic Stem Cell Age on CML Disease Progression PRINCIPAL INVESTIGATOR: Kenneth Dorshkind, Ph.D. CONTRACTING ORGANIZATION: University of California,
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationDone By : WESSEN ADNAN BUTHAINAH AL-MASAEED
Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We
More informationFuture of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
Future of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Primitive sleeping BCR-ABL-positive leukemic stem cells are less
More informationFunctional genomics reveal that the serine synthesis pathway is essential in breast cancer
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer Results Presented by Stacey Lin Lloyd Lab http://www.amsbio.com/expression-ready-lentiviral-particles.aspx Overview
More informationCan we classify cancer using cell signaling?
Can we classify cancer using cell signaling? Central hypotheses (big ideas) Alterations to signaling genes would cause leukemic cells to react in an inappropriate or sensitized manner to environmental
More informationOverview of mathematical biological models and their application in CML research
Overview of mathematical biological models and their application in CML research March 27 th 2015 Christina Fitzmaurice, MD, MPH Faculty discussants: Vivian Oehler, MD FHCRC/UW William Hazelton, PhD FHCRC
More informationReview. Ageing 2: Cancer! Review: Mutations. Mutations 2/14/11. The Raw Material for Evolution. The Double Edged Sword
Ageing 2: Cancer! Review: The force of natural selection declines with ageing due to increase in extrinsic mortality (= weakening of natural selection) and reduction in reproduction with age (selection
More informationNUTRITION & MALIGNANCY: An Overview
NUTRITION & MALIGNANCY: An Overview UNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ Temple 1 Malignancy and Weight loss (Cachexia)
More informationScientific report: Delineating cellular stages and regulation of human NK cell development to improve NK cell-based therapy for cancer (Dnr )
Scientific report: Delineating cellular stages and regulation of human NK cell development to improve NK cell-based therapy for cancer (Dnr 130259) The main goal of this project focuses on establishing
More informationCancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
More informationSupplementary Figure 1. Successful excision of genes from WBM lysates and
Supplementary Information: Supplementary Figure 1. Successful excision of genes from WBM lysates and survival of mice with different genotypes. (a) The proper excision of Pten, p110α, p110α and p110δ was
More informationTITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis
AD Award Number: W81XWH-05-1-0608 TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis PRINCIPAL INVESTIGATOR: Craig T. Jordan, Ph.D. CONTRACTING ORGANIZATION:
More informationHow Cancer Shapes Evolution and How Evolution Shapes Cancer
Evo Edu Outreach (2011) 4:624 634 DOI 10.1007/s12052-011-0373-y REVIEW How Cancer Shapes Evolution and How Evolution Shapes Cancer Matias Casás-Selves & James DeGregori Published online: 2 December 2011
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW
ADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW Danièle SOMMELET European Scientific Seminar Luxemburg, 3.11.2009 1 Definition of acute leukemias Malignant process coming from lymphoid (85 %)
More informationMutations and Disease Mutations in the Myosin Gene
Biological Sciences Initiative HHMI Mutations and Disease Mutations in the Myosin Gene Goals Explore how mutations can lead to disease using the myosin gene as a model system. Explore how changes in the
More informationStem Cells and Infec/ous Disease
Stem Cells and Infec/ous Disease Professor Vassie Ware Bioscience in the 21 st Century December 4, 2015 www.gothamgaze+e.com/.../stemcell/stem_cell.jpg Overview Se4ng the stage for the discussion: historical
More informationMINISYMPOSIUM MATHEMATICAL MODELING OF LEUKEMIA AND MYELOPROLIFERATIVE NEOPLASMS
Tuesday, July 24th, 10:30 MINISYMPOSIUM MATHEMATICAL MODELING OF LEUKEMIA AND MYELOPROLIFERATIVE NEOPLASMS Organizer Morten Andersen Roskilde University Denmark moan@ruc.dk Co-organizer Thomas Stiehl Heidelberg
More informationThe Importance of Glutamine and Antioxidant Vitamin Supplementation in HIV
The Importance of Glutamine and Antioxidant Vitamin Supplementation in HIV An Introduction to Glutamine Glutamine is the most abundant amino acid in the human body, and plays extremely important role in
More informationLeukemia Research Foundation Scientific Research Grant Recipients
Page 1 of 5 NEW INVESTIGATOR AWARDS Richard Dahl, Ph.D. University of New Mexico $75,000.00 - Ets and Gfi1 family interactions in T cell development T and B cells comprise the adaptive arm of the vertebrate
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature12215 Supplementary Figure 1. The effects of full and dissociated GR agonists in supporting BFU-E self-renewal divisions. BFU-Es were cultured in self-renewal medium with indicated GR
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationProgrammed Cell Death (apoptosis)
Programmed Cell Death (apoptosis) Stereotypic death process includes: membrane blebbing nuclear fragmentation chromatin condensation and DNA framentation loss of mitochondrial integrity and release of
More informationPhenotypes of Dyslipidemia A mechanis8c approach to management. Disclosures. Consultant FGH Research Funding Synageva, Inc.
Phenotypes of Dyslipidemia A mechanis8c approach to management John P. Kane, M.D., Ph.D. Professor of Medicine University of alifornia, San Francisco Disclosures onsultant FGH Research Funding Synageva,
More informationSubject Index. rationale for supplementation in cancer patients 260, 273 surgical cancer patient supplementation
Acute-phase response, cytokine mediation in cachexia 157, 158 ß 2 -Adrenergic agonist, effects on rat tumor models 264 Alcohol breast cancer studies 107, 108, 111, 112, 116 ß-carotene interactions 53 lung
More informationIntroduction to Cancer
Introduction to Cancer Clonal Evolution Theory of Tumor Development,2,2,,2,2,,2, Numbers represent sequential mutations to cellular genes Oncogenes and Tumor Suppresser Genes On Oncogenes Tumor Suppresser
More informationChronic Myeloid Leukemia Outlook: The Future of CML Therapy
Chronic Myeloid Leukemia Outlook: The Future of CML Therapy Neil Shah, MD PhD Edward S. AgenoDistinguished Professor in Hematology/Oncology UCSF School of Medicine San Francisco, California Progression
More informationFuture Targets for Acute Myeloid Leukemia
Future Targets for Acute Myeloid Leukemia E. Anders Kolb, M.D. Director, Nemours Center for Cancer and Blood Disorders Chair, Children s Oncology Group Myeloid Disease Committee Future Targets for Acute
More informationSession 5. Pre-malignant clonal hematopoietic proliferations. Chairs: Frank Kuo and Valentina Nardi
Session 5 Pre-malignant clonal hematopoietic proliferations Chairs: Frank Kuo and Valentina Nardi Pre-malignant clonal hematopoietic proliferations Clonal LYMPHOID proliferations: - Monoclonal gammopathy
More informationB and T cell Memory. Bengt Lindbom Adap6ve Immunity BMC D14
B and T cell Memory Bengt Lindbom Adap6ve Immunity BMC D14 Immunity: a historical perspec6ve 430 B.C. Thucydides describes the ongoing plague of Athens:.the same man was never attacked twice 15th century:
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationGlioblastoma pathophysiology: or a
Glioblastoma pathophysiology: A or a? M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Pathophysiology: pathophysiology seeks to explain the physiological
More informationTUMOR INITIATING CELLS: THE STEM CELL THEORY OF CANCER
Pr John DE VOS Département d Ingénierie Cellulaire et Tissulaire INSERM 1183 - IRMB Hôpital St Eloi - CHU de Montpellier john.devos@inserm.fr @_jdevos_ TUMOR INITIATING CELLS: THE STEM CELL THEORY OF CANCER
More informationSupplementary Material. Contents include:
Supplementary Material Contents include: 1. Supplementary Figures (p. 2-7) 2. Supplementary Figure Legends (p. 8-9) 3. Supplementary Tables (p. 10-12) 4. Supplementary Table Legends (p. 13) 1 Wellen_FigS1
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationCancer Genomes How to Analyze Your Own Genome
Cancer Genomes 02-223 How to Analyze Your Own Genome Cancer vs. Heritable Diseases So far, we mostly discussed heritable diseases, where the disease causing mutaaons are inherited from one individual to
More informationThe Role of Rac Signaling in The Perivascular Niche
The Role of Rac Signaling in The Perivascular Niche Felicia Ciuculescu Diaspora and Higher Education and Research Perspectives in Personalized Medicine- from Concept to Clinical Application Center for
More informationsequences of a styx mutant reveals a T to A transversion in the donor splice site of intron 5
sfigure 1 Styx mutant mice recapitulate the phenotype of SHIP -/- mice. (A) Analysis of the genomic sequences of a styx mutant reveals a T to A transversion in the donor splice site of intron 5 (GTAAC
More informationChildhood Leukemia Causes, Risk Factors, and Prevention
Childhood Leukemia Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for childhood
More informationDo acgh analysis have a place in routine cytogenetic workup in leukemia/cancer? - A single institution experience. Cambridge, April 9 th 2013
Do acgh analysis have a place in routine cytogenetic workup in leukemia/cancer? - A single institution experience. Cambridge, April 9 th 2013 Aarhus University Hospital Eigil Kjeldsen, Cancercytogenetic
More informationCancer as a Metabolic Disease
Cancer as a Metabolic Disease On the Origin, Management and Prevention of Cancer Thomas N. Seyfried @WILEY "" Forword Preface xiii xv 1. Images of Cancer 1 How Cancer is Viewed 2 References 13 2. Confusion
More informationIschemic Stroke Activates Hematopoietic Bone Marrow Stem Cells
Ischemic Stroke Activates Hematopoietic Bone Marrow Stem Cells Gabriel Courties*, Fanny Herisson*, Hendrik B. Sager, Timo Heidt, Yuxiang Ye, Ying Wei, Yuan Sun, Nicolas Severe, Partha Dutta, Jennifer Scharff,
More informationFaculty of Medicine Dr. Tariq Aladily
Iron deficiency anemia The most common anemia worldwide Only 10% of ingested iron is absorbed Most dietary iron occurs in meat products Absorbed in duodenum Hepcidin By inhibiting ferroportin, hepcidin
More informationIMMUNE RESPONSE TO INFECTIOUS DISEASES
IMMUNE RESPONSE TO INFECTIOUS DISEASES Immune Response to Bacterial Infection Characteris*cs of Bacteria 1 X 2 X 3 X 4 X 5 X 6 X 7 X Bacterial Diseases Any part of the body can be infected by many Infec;ous
More informationSUPPLEMENTARY INFORMATION
a. Smo+/+ b. Smo+/+ 5.63 5.48 c. Lin- d. e. 6 5 4 3 Ter119 Mac B T Sca1 Smo+/+ 25 15 2 o BMT 2 1 5 * Supplementary Figure 1: Deletion of Smoothened does not alter the frequency of hematopoietic lineages
More informationCANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)
CANCER Affects 25% of US population Kills 19% of US population (2nd largest killer after heart disease) NOT one disease but 200-300 different defects Etiologic Factors In Cancer: Relative contributions
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationJPEMS Nantes, Basic Immunology Introduction to the immune system Definitions Structure and General Organization
JPEMS Nantes, 2014- Basic Immunology Introduction to the immune system Definitions Structure and General Organization Teacher: Pr. Régis Josien, Laboratoire Immunologie and INSERM U1064, CHU Nantes Regis.Josien@univ-nantes.fr
More informationNature Immunology: doi: /ni Supplementary Figure 1. Huwe1 has high expression in HSCs and is necessary for quiescence.
Supplementary Figure 1 Huwe1 has high expression in HSCs and is necessary for quiescence. (a) Heat map visualizing expression of genes with a known function in ubiquitin-mediated proteolysis (KEGG: Ubiquitin
More informationExample: Distance in M.U. % Crossing Over Why? Double crossovers
Example: Distance in M.U. % Crossing Over 1 5 10 15 50 80 100 107 Why? Double crossovers 232 .. A B. a b. 1. A fully heterozygous gray-bodied (b+), normal winged (vg+) female F 1 fruit fly crossed with
More informationCTLA-4 regulates pathogenicity of antigen-specific autoreactive T cells by cell-intrinsic and -extrinsic mechanisms
Class 15, BBS821: Control of pathogenic self-reactive T cells by co-inhibitory molecules, J. Kang Oct 29, 2015 CTLA-4 regulates pathogenicity of antigen-specific autoreactive T cells by cell-intrinsic
More informationLecture 1: Carcinogenesis
Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer
More informationEHA an overview. Christine Chomienne EHA President.
EHA an overview Christine Chomienne EHA President www.ehaweb.org EHA activities Career development Calls are open now EHA Learning Center Annual congress EHA promotes excellence in research, education
More informationSection 9. Junaid Malek, M.D.
Section 9 Junaid Malek, M.D. Mutation Objective: Understand how mutations can arise, and how beneficial ones can alter populations Mutation= a randomly produced, heritable change in the nucleotide sequence
More informationComputational Systems Biology: Biology X
Bud Mishra Room 1002, 715 Broadway, Courant Institute, NYU, New York, USA L#4:(October-0-4-2010) Cancer and Signals 1 2 1 2 Evidence in Favor Somatic mutations, Aneuploidy, Copy-number changes and LOH
More informationShould Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!
Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!! Lindsay Anne Magura Rein, MD Division of Hematologic Malignancies and Cellular Therapy/BMT A Little Bit of History.. 1665 Advanced
More informationSUPPLEMENTAL APPENDIX
SUPPLEMENTAL APPENDIX Table of Contents 1. Supplemental Tables 2. Supplemental Figures Nature Medicine: doi:1.138/nm.4441 Supplemental Table 1. Baseline Characteristics of Patients Treated with anti-cd22
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More information2/23/2015. Metabolism and Energetcis. Metabolism and Energetics. Metabolism and Energetics
8 6 Metabolism and Energetcis Simple energy budget Calories ingested = Calories used + growth Frequency 4 Currency is typically (kilo)calories 1 calorie 1 g water 1 C o 4.2 Joules 2 0 90-100 80-90 70-80
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationLe nuove mutazioni oltre JAK2: IDH1/2 e LNK. Dr.ssa Lisa Pieri
Le nuove mutazioni oltre JAK2: IDH1/2 e LNK Dr.ssa Lisa Pieri First report of IDH1 muta5ons in myeloid malignancies: detected by sequencing an AML genome, preferen5ally clustering with intermediate risk
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationCancer stem cells old concepts, new insights
Review (2008) 15, 947 958 & 2008 Nature Publishing Group All rights reserved 1350-9047/08 $30.00 www.nature.com/cdd Cancer stem cells old concepts, new insights L Vermeulen 1, MR Sprick 1, K Kemper 1,
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationBiochemistry of Cancer and Tumor Markers
Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first
More informationSH/EAHP WORKSHOP 2017 CASE 210 PRESENTATION
SH/EAHP WORKSHOP 2017 CASE 210 PRESENTATION Jonathon H Gralewski DO, MS, Ginell R Post MD, PhD, Youzhong Yuan MD September 9, 2017 Clinical History 60 year old male with history of c-maf high-risk IgG
More informationChronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE
Chronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE If searched for the ebook by DEISSEROTH Chronic Myelogenous Leukemia (Hematology) in pdf format, in that case you come on to correct
More informationFunctional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells
University of Massachusetts Medical School escholarship@umms GSBS Student Publications Graduate School of Biomedical Sciences 2011-09-23 Functional ramifications for the loss of P-selectin expression on
More informationU.S. Low Dose Radiation Research Program
U.S. Low Dose Radiation Research Program Update November 2010 ISCORS NF Metting, ScD, Program Manager Office of Science Office of Biological and Environmental Research The Department of Energy Office of
More informationMicroevolution: The Forces of Evolutionary Change Part 2. Lecture 23
Microevolution: The Forces of Evolutionary Change Part 2 Lecture 23 Outline Conditions that cause evolutionary change Natural vs artificial selection Nonrandom mating and sexual selection The role of chance
More information609G: Concepts of Cancer Genetics and Treatments (3 credits)
Master of Chemical and Life Sciences Program College of Computer, Mathematical, and Natural Sciences 609G: Concepts of Cancer Genetics and Treatments (3 credits) Text books: Principles of Cancer Genetics,
More informationPyruvate Alanine 0.15 *** ** ***
SUPPLEMENTARY FIGURES Glucose ΔµM from fresh media / mg protein -1-2 -3 - -.1 -.3 -.5 Lactate Alanine Formate ΔµM from fresh media / mg protein 5 3 2 1.15.1.5.6..2.. NS-3 WT-NS G93A-NS Supplementary Figure
More information